SCHEMBL3548595

SCHEMBL3548595

Clc1[c]nccc1N1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ GAA P10253 3/20 0.44
▸ MAPT P10636 3/20 0.44
▸ PIK3CD O00329 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ PIK3CB P42338 1/20 0.41
▸ ALDH3A1 P30838 1/20 0.41
▸ ALDH1A3 P47895 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.39
▸ TSHR P16473 2/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ AKR1C3 P42330 2/20 0.39
▸ MAPK1 P28482 2/20 0.38
▸ THRB P10828 2/20 0.38
▸ NCF1 P14598 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15416096 0.79 ADRB1 (0.49) ALDH1A1NCF1
SCHEMBL3546491 0.79 PIK3CD (0.41) SMN1; SMN2GAAMAPTPIK3CDPIK3CA
SCHEMBL3548593 0.76 GAA (0.40) SMN1; SMN2GAAMAPTALDH3A1ALDH1A3
SCHEMBL17493416 0.76 PDE10A (0.40) SMN1; SMN2GAAMAPTPIK3CDPIK3CA
SCHEMBL3763677 0.74 PDE4A (0.46) SMN1; SMN2GAAMAPTALDH1A1TSHR
SCHEMBL3541167 0.70 MAPT (0.45) SMN1; SMN2GAAMAPTALDH3A1ALDH1A3
SCHEMBL7674618 0.69 HRH3 (0.37) PIK3CDPIK3CAPIK3CBNPSR1KDM4E
SCHEMBL3546488 0.69 POLB (0.39) SMN1; SMN2GAAMAPTALDH1A1KDM4E
SCHEMBL15415321 0.69 ALDH1A1 (0.40) SMN1; SMN2GAAMAPTALDH1A1TSHR
SCHEMBL441105 0.68 LMNA (0.42) SMN1; SMN2GAAMAPTPIK3CAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 — — US claimed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 — — US claimed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 — — EP claimed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 — — WO claimed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 — — US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 — — US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 — — US disclosed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 — — EP disclosed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 SMN1; SMN2 4452/4885GAA 171/4885MAPT 2115/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 SMN1; SMN2 4458/4885GAA 163/4885MAPT 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback